Literature DB >> 19215246

Comparison of proactive and usual approaches to offering predictive testing for BRCA1/2 mutations in unaffected relatives.

D G R Evans1, A Binchy, A Shenton, P Hopwood, D Craufurd.   

Abstract

There have been few studies addressing uptake of predictive testing for BRCA1/2, only one comparing a proactive with usual family networking approach to dissemination. We report uptake of predictive genetic testing after directly offering BRCA1 presymptomatic genetic testing to 100 individuals in two generations of 5 large BRCA1 families compared with service testing of 196 families since that time. Uptake was significantly higher in the first generation (group 1), who were directly offered testing, and much higher in females. Seventy-four percent of unaffected women in the first generation proceeded to testing, 42% of men. This decreased to 44% of women in the second generation (group 2) and 9% males (p = 0.0003). Uptake in unaffected individuals in the final group (group 3) with no proactive approach was significantly lower than that in the first group. Overall uptake after 10 years was 56% (95% confidence interval, CI, 50-62%) for group 1 and 36% (95% CI 34.3-37.7%) for 1084 group 3 individuals (p = 0.0003). Among women, uptake was 74% (95% CI 67-81%) in group 1 at 10 years compared with 51.5% (95% CI 49-54%) in 552 group 3 women (p = 0.023). In men, uptake was 42% (95% CI 33-52%) in group 1 and 21.1% (95% CI 18.1-23.1%) among 532 men in group 3 (p = 0.0098). Although these results are not from a randomized trial, they show particularly among men a substantially higher uptake of genetic services with a direct approach. Importance should be given to more proactive approaches to ensure that men in BRCA1/2-positive families receive the appropriate information.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19215246     DOI: 10.1111/j.1399-0004.2008.01146.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  14 in total

1.  The uptake of presymptomatic genetic testing in hereditary breast-ovarian cancer and Lynch syndrome: a systematic review of the literature and implications for clinical practice.

Authors:  Fred H Menko; Jacqueline A Ter Stege; Lizet E van der Kolk; Kiki N Jeanson; Winnie Schats; Daoud Ait Moha; Eveline M A Bleiker
Journal:  Fam Cancer       Date:  2019-01       Impact factor: 2.375

2.  Informing family members of individuals with Lynch syndrome: a guideline for clinical geneticists.

Authors:  Fred H Menko; Cora M Aalfs; Lidewij Henneman; Yrrah Stol; Miranda Wijdenes; Ellen Otten; Marleen M J Ploegmakers; Johan Legemaate; Ellen M A Smets; Guido M W R de Wert; Aad Tibben
Journal:  Fam Cancer       Date:  2013-06       Impact factor: 2.375

3.  Within-Gender Differences in Medical Decision Making Among Male Carriers of the BRCA Genetic Mutation for Hereditary Breast Cancer.

Authors:  Sharlene Hesse-Biber; Chen An
Journal:  Am J Mens Health       Date:  2015-10-14

4.  Prospective Feasibility Trial of a Novel Strategy of Facilitated Cascade Genetic Testing Using Telephone Counseling.

Authors:  Melissa K Frey; Ryan M Kahn; Eloise Chapman-Davis; Francesca Tubito; Maira Pires; Paul Christos; Samantha Anderson; Semanti Mukherjee; Bailey Jordan; Stephanie V Blank; Thomas A Caputo; Ravi N Sharaf; Kenneth Offit; Kevin Holcomb; Steven Lipkin
Journal:  J Clin Oncol       Date:  2020-01-10       Impact factor: 44.544

5.  Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study.

Authors:  Anita V Mitra; Elizabeth K Bancroft; Yolanda Barbachano; Elizabeth C Page; C S Foster; C Jameson; G Mitchell; G J Lindeman; A Stapleton; G Suthers; D G Evans; D Cruger; I Blanco; C Mercer; J Kirk; L Maehle; S Hodgson; L Walker; L Izatt; F Douglas; K Tucker; H Dorkins; V Clowes; A Male; A Donaldson; C Brewer; R Doherty; B Bulman; P J Osther; M Salinas; D Eccles; K Axcrona; I Jobson; B Newcombe; C Cybulski; W S Rubinstein; S Buys; S Townshend; E Friedman; S Domchek; T Ramon Y Cajal; A Spigelman; S H Teo; N Nicolai; N Aaronson; A Ardern-Jones; C Bangma; D Dearnaley; J Eyfjord; A Falconer; H Grönberg; F Hamdy; O Johannsson; V Khoo; Z Kote-Jarai; H Lilja; J Lubinski; J Melia; C Moynihan; S Peock; G Rennert; F Schröder; P Sibley; M Suri; P Wilson; Y J Bignon; S Strom; M Tischkowitz; A Liljegren; D Ilencikova; A Abele; K Kyriacou; C van Asperen; L Kiemeney; D F Easton; Rosalind A Eeles
Journal:  BJU Int       Date:  2010-09-14       Impact factor: 5.588

6.  Interest of individuals from BRCA families to participate in research studies focused on male BRCA carriers.

Authors:  Tuya Pal; Susan Vadaparampil; Jongphil Kim; Yan Xu; Sue Friedman; Steven A Narod; Kelly Metcalfe
Journal:  Fam Cancer       Date:  2013-12       Impact factor: 2.375

7.  Facilitated cascade testing (FaCT): a randomized controlled trial.

Authors:  Roni Nitecki; Haley A Moss; Catherine H Watson; Diana L Urbauer; Alexander Melamed; Karen H Lu; Steven M Lipkin; Kenneth Offit; Jose Alejandro Rauh-Hain; Melissa K Frey
Journal:  Int J Gynecol Cancer       Date:  2020-12-18       Impact factor: 3.437

Review 8.  Health-care professionals' responsibility to patients' relatives in genetic medicine: a systematic review and synthesis of empirical research.

Authors:  Sandi Dheensa; Angela Fenwick; Shiri Shkedi-Rafid; Gillian Crawford; Anneke Lucassen
Journal:  Genet Med       Date:  2015-06-25       Impact factor: 8.822

9.  Approaching confidentiality at a familial level in genomic medicine: a focus group study with healthcare professionals.

Authors:  Sandi Dheensa; Angela Fenwick; Anneke Lucassen
Journal:  BMJ Open       Date:  2017-02-03       Impact factor: 2.692

10.  The impact of an interventional counselling procedure in families with a BRCA1/2 gene mutation: efficacy and safety.

Authors:  Erica Sermijn; Liesbeth Delesie; Ellen Deschepper; Ingrid Pauwels; Maryse Bonduelle; Erik Teugels; Jacques De Grève
Journal:  Fam Cancer       Date:  2016-04       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.